14-day Premium Trial Subscription Sign Up For FreeGet Free

BioCryst Pharmaceuticals Stock Forecast NASDAQ:BCRX

Price Target and Analyst Ratings

Most Recent Rating

On September 16, 2021 "JMP Securities" gave "$23.00" rating for BCRX. The price target was set to $15.20+0.9%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-09-16 $23.00 Reiterated by JMP Securities $15.21 $15.20+0.9%
2021-08-06 $18.00 - $30.00 Reiterated by HC Wainwright $17.61 $17.65+8.5%
2021-08-06 $18.00 - $30.00 Target Raised by HC Wainwright $17.61 $18.33+3.9%
2021-08-06 $13.00 - $16.00 Target Raised by Royal Bank of Canada $17.61 $17.50→0.8%
2021-08-06 Downgraded by Jefferies Financial Group $17.61 $17.50→0.8%
2021-08-06 $22.00 - $23.00 Target Raised by JMP Securities $17.61 $17.50→0.8%
2021-08-06 $20.00 - $21.00 Target Raised by Barclays $17.61 $17.65+8.5%
2021-08-05 $18.00 - $22.00 Target Raised by Piper Sandler $17.65 $17.67+8.7%
2021-08-03 $21.00 Initiated by Cantor Fitzgerald $16.76 $16.10→0.1%
2021-06-17 Outperform Target Raised by Cowen $16.36 $18.00 → $21.00
2021-05-28 Overweight Target Raised by Piper Sandler $15.77 $15.00 → $18.00
2021-05-07 Target Raised by Evercore ISI $13.12 $16.00 → $20.00
2021-05-07 Overweight Target Raised by Barclays $13.12 $13.00 → $20.00
2021-04-15 Hold Reiterated by Needham & Company LLC $11.34
2021-03-30 Buy Target Raised by HC Wainwright $9.99 $14.00 → $19.00
2021-03-24 Buy Target Raised by HC Wainwright $10.53 $14.00 → $19.00
2021-03-17 Positive - Overweight Target Raised by JPMorgan Chase & Co. $13.24 $10.00 → $15.00
2021-03-17 Positive - Overweight Reiterated by JPMorgan Chase & Co. $13.24 $10.00 → $15.00
2021-03-01 Outperform Initiated by Cowen $11.98 $16.00
2021-02-26 Overweight Target Raised by Barclays $10.78 $9.00 → $13.00
2021-01-22 Sector Perform Target Raised by Royal Bank of Canada $9.21 $7.00 → $9.00
2020-12-07 Buy Target Raised by HC Wainwright $7.22 $13.00 → $14.00
2020-12-07 Buy Reiterated by HC Wainwright $7.22 $13.00 → $14.00
2020-11-23 Outperform Initiated by Evercore ISI $4.40 $12.00
2020-11-23 Outperform Initiated by Evercore ISI $4.40
2020-10-04 Buy Reiterated by Bank of America $3.37 $6.00
2020-09-29 Overweight Initiated by JPMorgan Chase & Co. $3.84
2020-08-28 Hold Reiterated by Royal Bank of Canada $3.97 $4.50
2020-08-07 Buy Reiterated by HC Wainwright $3.97 $13.00
2020-07-06 Hold Reiterated by Royal Bank of Canada $4.95 $5.00
2020-06-26 Outperform Target Raised by JMP Securities $4.83 $10.00 → $11.00
2020-06-16 Neutral Initiated by BTIG Research $4.37
2020-05-07 Hold Reiterated by Royal Bank of Canada $3.92 $4.00
2020-05-06 Target Raised by Piper Sandler $3.86 $8.00 → $10.00
2020-05-06 Hold Reiterated by Needham & Company LLC $3.86
2020-05-05 Equal Weight - Overweight Upgraded by Barclays $3.95 $4.00 → $7.00

BCRX Stock Trend

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -8.04% during the next 3 months and, with a 90% probability hold a price between $12.66 and $14.61 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-22 $13.75 $14.81 $15.86
2021-09-23 $13.72 $14.78 $15.84
2021-09-24 $13.70 $14.76 $15.82
2021-09-27 $13.68 $14.74 $15.80
2021-09-28 $13.66 $14.72 $15.78
2021-09-29 $13.64 $14.69 $15.75
2021-09-30 $13.61 $14.67 $15.73
2021-10-01 $13.59 $14.65 $15.71
2021-10-04 $13.57 $14.63 $15.69
2021-10-05 $13.55 $14.61 $15.66
2021-10-06 $13.53 $14.58 $15.64
2021-10-07 $13.50 $14.56 $15.62
2021-10-08 $13.48 $14.54 $15.60
2021-10-11 $13.46 $14.52 $15.58
2021-10-12 $13.44 $14.50 $15.55
2021-10-13 $13.42 $14.47 $15.53
2021-10-14 $13.39 $14.45 $15.51
2021-10-15 $13.37 $14.43 $15.49
2021-10-18 $13.35 $14.41 $15.47
2021-10-19 $13.33 $14.39 $15.44
2021-10-20 $13.31 $14.36 $15.42
2021-10-21 $13.28 $14.34 $15.40
2021-10-22 $13.26 $14.32 $15.38
2021-10-25 $13.24 $14.30 $15.36
2021-10-26 $13.22 $14.28 $15.33
2021-10-27 $13.20 $14.25 $15.31
2021-10-28 $13.17 $14.23 $15.29
2021-10-29 $13.15 $14.21 $15.27
2021-11-01 $13.13 $14.19 $15.25
2021-11-02 $13.11 $14.17 $15.22

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II/III clinical trial for hereditary angioedema (HAE); BCX7353, ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT